BerGenBio is focused on developing a pipeline of transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
Pipeline
- Product/Indication
- Discovery
- Lead optimisation
- Preclincal
- Phase 1
- Phase 2
- Phase 3
bemcentinib
Indication: NSCLC
Combination: KEYTRUDA
Partner: Merck Inc
Phase 2 B
bemcentinib
Indication: NSCLC
Combination: TARCEVA
Phase 2 B
bemcentinib
Indication: NSCLC
Combination: docetaxel
Partner: UTSW Medical Center
Phase 2 A
bemcentinib
Indication: TNBC
Target: KEYTRUDA
Partner: Merck Inc.
Phase 2 B
bemcentinib
Indication: Melanoma
Combination: KEYTRUDA / TAFINLAR, MEKINIST
Partner: Bergen University Hospital
Phase 2 B
bemcentinib
Indication: AML
Combination: single agent / cytarabine, decitabine
Phase 2 B
BGB149
Indication: Cancer
Target: AXL
Preclincal (end) - Phase 1 A
BGB601
Indication: Cancer
Target: AXL-ADC
Preclincal (end) - Phase 1 A
Discovery
Indication: Cancer
Target: undisclosed
Lead optimization (end) - Preclincal (begin)
BerGenBio Asset
Outlicensed
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159